Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ELOVL6 | Q9H5J4 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094096 | 0.93 | HRH3 (0.40) | HRH3SLC6A4NPC1HRH2HRH1 | |
| SCHEMBL2959501 | 0.90 | KCNH2 (0.38) | HRH3SLC6A4NPC1HRH2HRH1 | |
| SCHEMBL6993367 | 0.89 | HRH3 (0.40) | HRH3SLC6A4HRH2HRH1MEN1 | |
| SCHEMBL5965915 | 0.87 | NPC1 (0.37) | HRH3SLC6A4NPC1HRH2HRH1 | |
| SCHEMBL5965518 | 0.86 | HRH3 (0.39) | HRH3SLC6A4NPC1HRH2HRH1 | |
| SCHEMBL6997329 | 0.85 | SLC6A4 (0.39) | HRH3SLC6A4HRH2HRH1DRD3 | |
| SCHEMBL6990939 | 0.85 | HRH3 (0.42) | HRH3SLC6A4HRH2HRH1DRD3 | |
| SCHEMBL6992027 | 0.85 | HRH3 (0.39) | HRH3SLC6A4HRH2HRH1DRD3 | |
| SCHEMBL6740792 | 0.84 | SLC6A4 (0.41) | HRH3SLC6A4HRH2HRH1MEN1 | |
| SCHEMBL6991661 | 0.83 | HRH3 (0.41) | HRH3SLC6A4HRH2HRH1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1301510-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004446-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | HRH3 402/4885SLC6A4 1139/4885NPC1 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.